Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Characterizing mechanism of inhibition of Cathepsin K by novel exosite inhibitors
FY 2014-15
Summary
Osteoporosis is the cause of over 80% of all fractures which occur in people over the age of 50. Osteoporosis occurs when bones are being degraded faster than they are being repaired during the remodelling process which is constantly occurring. Cathepsin K is an enzyme found in cells responsible for degrading bones and the enzyme acts by degrading the collagen in our bones. Unsurprisingly, this enzyme is a great target for inhibition by drugs. However, cathepsin K is also known to have functions other than collagen degradation so the enzyme must be inhibited in such a way that only the collaged degradation ability is stopped. The most common way to design a drug is to target the active site of the enzyme, which is the part of the protein responsible for carrying out its function. Drugs currently being studied for osteoporosis treatment target the active site of cathepsin K and inhibit all activity of the enzyme. This has resulted in side effects occurring during clinical trials. Recently, targeting “exosites” has gained attention as a new method inhibiting enzymes. Exosites are sites that are far from the protein’s active site and drugs that bind these sites can specifically inhibit only one function of a protein; in this case, the degradation of collagen by cathepsin K. My project as a graduate student will be on understanding how molecules that bind exosites cause inhibition of an enzyme. I will do so by determining how the enzyme behaves with inhibitors, what the structure of a inhibitor-protein complex looks like and what happens when the drugs are no longer able to bind cathepsin K. Successful exosite inhibitors of cathepsin K will hugely benefit the large number of Canadians experiencing osteoporotic fractures in their lifetime.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
331375
Name
Dalwadi Udit
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing mechanism of inhibition of Cathepsin K by novel exosite inhibitors
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Allosteric Mechanism; Drug Development; Enzymology; Osteoporosis; Rheumatoid Arthritis; X-Ray Crystallography
Abstract
Osteoporosis is the cause of over 80% of all fractures which occur in people over the age of 50. Osteoporosis occurs when bones are being degraded faster than they are being repaired during the remodelling process which is constantly occurring. Cathepsin K is an enzyme found in cells responsible for degrading bones and the enzyme acts by degrading the collagen in our bones. Unsurprisingly, this enzyme is a great target for inhibition by drugs. However, cathepsin K is also known to have functions other than collagen degradation so the enzyme must be inhibited in such a way that only the collaged degradation ability is stopped. The most common way to design a drug is to target the active site of the enzyme, which is the part of the protein responsible for carrying out its function. Drugs currently being studied for osteoporosis treatment target the active site of cathepsin K and inhibit all activity of the enzyme. This has resulted in side effects occurring during clinical trials. Recently, targeting “exosites” has gained attention as a new method inhibiting enzymes. Exosites are sites that are far from the protein’s active site and drugs that bind these sites can specifically inhibit only one function of a protein; in this case, the degradation of collagen by cathepsin K. My project as a graduate student will be on understanding how molecules that bind exosites cause inhibition of an enzyme. I will do so by determining how the enzyme behaves with inhibitors, what the structure of a inhibitor-protein complex looks like and what happens when the drugs are no longer able to bind cathepsin K. Successful exosite inhibitors of cathepsin K will hugely benefit the large number of Canadians experiencing osteoporotic fractures in their lifetime.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Dalwadi, Udit
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~